Rexahn Pharmaceuticals Inc (RNN)

2.45
0.04 1.70
AMEX : Health Care
Prev Close 2.41
Open 2.38
Day Low/High 2.36 / 2.48
52 Wk Low/High 0.24 / 0.65
Volume 128.98K
Avg Volume 211.60K
Exchange AMEX
Shares Outstanding 28.46M
Market Cap 66.31M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress

RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Advanced Bladder Cancer Resistant to Gemcitabine who had failed on Multiple Prior Treatments

Rexahn Pharmaceuticals Receives New U.S. Patent For Supinoxin™

Rexahn Pharmaceuticals Receives New U.S. Patent For Supinoxin™

Patent Protection Extended until 2034

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-3117

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-3117

Patent Protection for RX-3117 Extended until 2036

Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective

Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent

Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent

RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences

Rexahn Pharmaceuticals Strengthens Leadership Team

Rexahn Pharmaceuticals Strengthens Leadership Team

Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer